Oncotarget:科学家鉴别出可促进乳腺癌发生转移的特殊靶向基因

2015-06-18 佚名 生物谷

一种特殊的人类基因突变体或可使乳腺癌细胞变得更加具有攻击性,从而使得乳腺癌细胞不仅对化疗产生耐药,而且使得原发性肿瘤开始扩散;近日来自维也纳医科大学的研究人员通过研究发现,名为AF1q的基因或可使得乳腺癌细胞变得更加具有侵略性,同时该基因或许也可以作为一种新型靶点来帮助开发治疗乳腺癌的靶向性疗法。 人类机体的AF1q基因是在染色体异常时发现的,而且该基因被认为是白血病发生的重要因子,同时研究

一种特殊的人类基因突变体或可使乳腺癌细胞变得更加具有攻击性,从而使得乳腺癌细胞不仅对化疗产生耐药,而且使得原发性肿瘤开始扩散;近日来自维也纳医科大学的研究人员通过研究发现,名为AF1q的基因或可使得乳腺癌细胞变得更加具有侵略性,同时该基因或许也可以作为一种新型靶点来帮助开发治疗乳腺癌的靶向性疗法。

人类机体的AF1q基因是在染色体异常时发现的,而且该基因被认为是白血病发生的重要因子,同时研究者在急性髓性白血病中发现AF1q基因的水平较高。目前AF1q基因在人类机体中的功能并没有被完全阐明,但本文研究却首次发现AF1q基因是TCF7/Wnt信号通路中的关键蛋白,其可以控制癌细胞的行为,该基因表达的增加会促进肿瘤细胞的发育和生长,同时会抑制天然的细胞死亡,而AF1q基因显著表达的乳腺癌患者往往预后较差,而且AF1q基因阳性的癌细胞对化疗更容易产生耐受性。

后期研究中,研究者发现乳腺癌细胞中AF1q的表达会促进癌细胞在肝脏和肺脏中的转移,当研究者将原发性的肿瘤样本同转移性的样本进行对比后发现,AF1q阳性的癌细胞会不断发生转移,而且目前有很多研究证据表明,AF1q高度表达的癌细胞或可作为癌症转移的专项细胞来进行工作,这些癌细胞可以迁移到机体的其它部位建立肿瘤组织并且进一步扩散。

因此AF1q基因表达的增加或许可以作为预测癌症患者预后较差的一个指标,然而AF1q同时也可以被用于作为开发新型疗法的靶点,后期研究人员还将通过更为深入的研究来阐明该基因为何会促进乳腺癌细胞发生转移,同时他们还将开发新型的靶向个体化疗法来有效抑制乳腺癌的转移。

原始出处:

Park J1, Schlederer M2,3, Schreiber M4, Ice R5,6, Merkel O7, Bilban M8, Hofbauer S4, Kim S1, Addison J5,6, Zou J9, Ji C9, Bunting ST10, Wang Z10, Shoham M11, Huang G12, Bago-Horvath Z3, Gibson LF5, Rojanasakul Y5,13, Remick S5, Ivanov A5,6, Pugacheva E5,6, Bunting KD10, Moriggl R2,14, Kenner L2,3,15, Tse W1.AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis.Oncotarget. 2015 Jun 7. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=49603, encodeId=421749603fe, content=好学习很值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:26:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795318, encodeId=5f161e95318b3, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Jul 25 04:28:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29220, encodeId=d02a2922068, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28553, encodeId=df08285530e, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28429, encodeId=b3a12842949, content=(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:33:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28430, encodeId=a4592843011, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:33:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-12-27 忠诚向上

    好学习很值得

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=49603, encodeId=421749603fe, content=好学习很值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:26:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795318, encodeId=5f161e95318b3, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Jul 25 04:28:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29220, encodeId=d02a2922068, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28553, encodeId=df08285530e, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28429, encodeId=b3a12842949, content=(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:33:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28430, encodeId=a4592843011, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:33:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-07-25 闆锋旦
  3. [GetPortalCommentsPageByObjectIdResponse(id=49603, encodeId=421749603fe, content=好学习很值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:26:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795318, encodeId=5f161e95318b3, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Jul 25 04:28:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29220, encodeId=d02a2922068, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28553, encodeId=df08285530e, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28429, encodeId=b3a12842949, content=(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:33:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28430, encodeId=a4592843011, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:33:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=49603, encodeId=421749603fe, content=好学习很值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:26:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795318, encodeId=5f161e95318b3, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Jul 25 04:28:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29220, encodeId=d02a2922068, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28553, encodeId=df08285530e, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28429, encodeId=b3a12842949, content=(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:33:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28430, encodeId=a4592843011, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:33:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-21 erhong

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=49603, encodeId=421749603fe, content=好学习很值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:26:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795318, encodeId=5f161e95318b3, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Jul 25 04:28:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29220, encodeId=d02a2922068, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28553, encodeId=df08285530e, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28429, encodeId=b3a12842949, content=(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:33:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28430, encodeId=a4592843011, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:33:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-21 18619c0a62m

    (⊙o⊙)

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=49603, encodeId=421749603fe, content=好学习很值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:26:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795318, encodeId=5f161e95318b3, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Jul 25 04:28:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29220, encodeId=d02a2922068, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:04:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28553, encodeId=df08285530e, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bae01627531, createdName=erhong, createdTime=Sun Jun 21 20:20:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28429, encodeId=b3a12842949, content=(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:33:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28430, encodeId=a4592843011, content=!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 16:33:00 CST 2015, time=2015-06-21, status=1, ipAttribution=)]
    2015-06-21 18619c0a62m

    !!!

    0

相关资讯

BMC Cancer: 新技术可通过检测尿液来帮助诊断乳腺癌

近日,刊登在国际杂志BMC Cancer上的一篇研究论文中,来自弗莱堡大学的研究人员通过研究开发了一种新技术,其可以通过分析尿液样本来帮助检测乳腺癌,这种方法可以确定调节细胞代谢的分子microRNAs的水平,而通常在癌细胞中microRNAs的水平会失调;通过确定尿液中microRNAs的组成,研究人员就可以使得该技术诊断乳腺癌的成功率达到91%。 世界上大约有170万女性患乳腺癌,同时乳腺癌

NEJM: 乳腺癌手术患者特别注意事项

根据耶鲁癌症中心的研究发现,在部分乳房切除术时,移除更多一些的组织可以为成千上万的乳腺癌患者省去第二次手术。这项发现于5月30日在线发表在New England Journal of Medicine杂志上,且在2015年芝加哥举行的美国临床癌症协会年会上有所报道。 在美国,每年近30万女性被诊断为乳腺癌,超过一半的患者接受部分乳房切除术来移除病灶,同时保留部分乳腺。然而,大约20%到40%

ASCO 2015:两项乳腺癌靶向治疗研究---CALGB 40503和NeoSpher研究

河南省肿瘤医院 河南省乳腺病诊疗中心 闫敏 发自 美国芝加哥研究1:评价贝伐珠单抗加来曲唑一线治疗激素受体阳性转移性乳腺癌的Ⅲ期临床研究(CALGB 40503)报告者:美国纽约纪念斯隆-凯特林癌症中心Maura N. Dickler摘要号:501背景:临床前研究表明,雌激素可在生理和病理条件下调节血管生成,乳腺肿瘤中血管内皮生长因子(VEGF)的高表达与降低内分泌治疗反应性相关,研究者开展了一项

NEJM:乳腺癌筛查指南更新——IARC观点

乳腺癌筛查的目的是通过对无症状女性进行早期检测,降低这种癌症的死亡率,以及与疾病晚期相关的发病率。使筛查的作用达到最大化的关键是早期获取有效的诊断和治疗。而筛查的综合质量是保持筛查利弊平衡的重中之重。  6月3日《新英格兰医学杂志》(New Engl J Med)在线发布国际癌症研究机构(IARC)乳腺癌筛查指南。IARC此次对其2002发布的乳腺癌筛查手册的更新主要基于以下几个方面原因。1.晚期

另类乳腺癌宣传:「胸夹可乐」大挑战?

与去年夏天兴起的冰桶挑战相比,今年的“胸夹可乐”挑战[hold a coke with your boobs challenge]让人很难去在乎这种做法的目的是什么,说是为了让人们关注乳腺癌,其实没有什么其他目的,就是为了找个借口秀胸部罢了。 和之前的把铅笔放在袜子里来宣传睾丸癌的做法,以及其他许多你可能记得在社交网络上出现过的其他一些引人注意的“宣传”一样,这次的胸夹可乐挑战让人们能够展示他们

PNAS:TLR4——乳腺癌中的“双面人”

近日,来自美国德克萨斯MD安德森癌症中心的研究人员发现抑制免疫受体蛋白TLR4可能并不适用于治疗所有癌,TLR4在乳腺癌中既可促进癌细胞生长也可抑制癌细胞生长,而这种看似矛盾的作用则主要取决于TP53发生的突变类型。这项研究结果最近发表在国际学术期刊PNAS上。   TLR4有许多同家族成员,是参与许多免疫学途径的重要受体分子,之前许多研究证明TLR4是一个癌基因,能够促进肿瘤生长,